



ENTYVIO® (VEDOLIZUMAB) REFERRAL

(* - Required Fields)

____ **STAT REQUEST**
(*REASON MUST BE PROVIDED BELOW)

<input type="checkbox"/> New Referral	<input type="checkbox"/> Referral Renewal	<input type="checkbox"/> Medication/Order Change
<input type="checkbox"/> Benefits Verification Only	<input type="checkbox"/> Discontinuation Order	

PATIENT INFORMATION			
NAME*:	DOB*:	SEX: M F	
ADDRESS:		PHONE:	
WEIGHT:	LBS KG	HEIGHT:	EMAIL:
ALLERGIES:			

PHYSICIAN INFORMATION			
PHYSICIAN NAME*:		PRACTICE NAME:	
ADDRESS:		OFFICE CONTACT*:	
PHONE:	FAX:	EMAIL (FOR UPDATES):	

<p>ENTYVIO Infusion*: <small>(SELECT ONE OF THE FOLLOWING)</small></p> <p>Initial/Reloading Dosing and then Maintenance Dosing: <input type="checkbox"/> 300mg IV on weeks 0, 2, 6 weeks and then every _____ weeks</p> <p>OR</p> <p><input type="checkbox"/> Maintenance Dosing: 300mg IV every _____ weeks</p>	<p>ICD-10*: _____</p>
Physician Signature* _____ <small>*NPI # _____</small>	Date*(Order is Valid for One Year) _____ <small>Infusion will be administered per MPP policy and protocols</small>

REQUIRED DIAGNOSIS:
<input type="checkbox"/> Crohn's Disease <input type="checkbox"/> Ulcerative Colitis <input type="checkbox"/> Other _____
<p>*STAT REASON: (STAT requests will be assessed per MPP policy and protocols)</p>

REQUIRED DOCUMENTATION CHECKLIST:
<input type="checkbox"/> Patient Demographics <input type="checkbox"/> Insurance Card/Information <input type="checkbox"/> Clinical/Progress Notes supporting DX <input type="checkbox"/> Current Medication List and H&P
Last Infusion/Injection Date: _____

STANDING LAB ORDERS (to be drawn at clinic): CMP CBC *Frequency _____

FOR MPP USE ONLY	
Referral Reviewed and Accepted by: _____	Date approved: _____
Additional information needed/ notes:	

- Locations:**
- Colorado-----
 Lakewood
- Florida-----
 Jacksonville
 Kissimmee
 Port St. Lucie
 Suncoast
 Winter Park
- Oklahoma-----
 Tulsa
- Texas-----
 Arlington
 Cedar Hill
 Dallas
 Denton
 Ft. Worth
 Irving
 Rockwall
 Southlake
 Flower Mound
 Plano
 Tyler
- REVISION DATE- 01/2022